Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://cgoncology.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 22 min agoDividend
Analysts recommendations
Institutional Ownership
CGON Latest News
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monotherapy BOND-003 study – – Initiated and dosed first patient in Expanded Access Program for Cretostimogene Grenadenorepvec; Enrollment ongoing – IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the second quarter ended June 30, 2024, and provided business updates.
CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond to the BCG vaccine, but intermediate-risk patients could bring the addressable market above 60,000. Cretostimogene is the company's only asset and there is likely to be significant competition, most likely from Johnson & Johnson.
IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS).
What type of business is CG Oncology Common stock?
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
What sector is CG Oncology Common stock in?
CG Oncology Common stock is in the Healthcare sector
What industry is CG Oncology Common stock in?
CG Oncology Common stock is in the Biotechnology industry
What country is CG Oncology Common stock from?
CG Oncology Common stock is headquartered in United States
What is CG Oncology Common stock website?
https://cgoncology.com
Is CG Oncology Common stock in the S&P 500?
No, CG Oncology Common stock is not included in the S&P 500 index
Is CG Oncology Common stock in the NASDAQ 100?
No, CG Oncology Common stock is not included in the NASDAQ 100 index
Is CG Oncology Common stock in the Dow Jones?
No, CG Oncology Common stock is not included in the Dow Jones index
When was CG Oncology Common stock the previous earnings report?
No data
When does CG Oncology Common stock earnings report?
The next expected earnings date for CG Oncology Common stock is 28 February 2025